title: Short interval follow-up after a benign concordant MR-guided vacuum assisted breast biopsy--is it worthwhile?
abstract: OBJECTIVE
  To determine the utility of short-interval follow-up after benign concordant MRI-guided breast biopsy.
  
  
  METHODS
  Institutional review board approved, retrospective review of consecutive biopsies performed over 3 years (2007-10) yielded 170 women with 188 lesions that were considered benign concordant. Indication for original study, biopsy results, follow-up recommendations, compliance and outcomes of subsequent MRI and mammography examinations were reviewed.
  
  
  RESULTS
  The most common indication for breast MRI was high-risk screening 119/170 (70 %). Overall, 59 % of lesions (113/188) had follow-up MRI. Of those lesions (n = 113), 43 % (49/113) presented within 7 months, 26 % (29/113) presented within 8-13 months, 11.5 % (13/113) presented within 14-22 months, and 19 % (22/113) presented after 23 months. At initial follow-up, 37 % of lesions were stable and 61 % were decreased in size. Three lesions were recommended for excision based on follow-up imaging with one malignancy diagnosed 2 years following biopsy. One additional patient had MRI-detected bilateral cancers remote from the biopsy site 3 years after biopsy.
  
  
  CONCLUSIONS
  Overall cancer yield of lesions with follow-up MRI was 0.9 % (1/113); no cancers were detected at 6 months. Our data suggests that 6-month follow-up may not be required and that annual screening MRI would be acceptable to maintain a reasonable cancer detection rate.
  
  
  CONCLUSIONS
  Follow-up recommendations after benign concordant MRI-guided breast biopsy remain controversial. Cancer detection rate was 0.9 % overall with no cancers detected at 6 months. Short-interval follow-up after benign concordant MRI-guided breast biopsy may not be necessary.
authors.affiliation: Department of Radiology, NYU School of Medicine, New York, NY, 10016, USA, sara.shaylor@nyumc.org.
authors.forename: Sara D
authors.initials: SD
authors.lastname: Shaylor
authors.forename: Samantha L
authors.initials: SL
authors.lastname: Heller
authors.forename: Amy N
authors.initials: AN
authors.lastname: Melsaether
authors.forename: Dipti
authors.initials: D
authors.lastname: Gupta
authors.forename: Avani
authors.initials: A
authors.lastname: Gupta
authors.forename: James
authors.initials: J
authors.lastname: Babb
authors.forename: Linda
authors.initials: L
authors.lastname: Moy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy / Q000379:methods; D001940:Breast / Q000473:pathology*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology*; D005260:Female; D018226:Fibroadenoma / Q000000981:diagnostic imaging / Q000473:pathology*; D005348:Fibrocystic Breast Disease / Q000000981:diagnostic imaging / Q000473:pathology; D005500:Follow-Up Studies; D018324:Hemangioma, Capillary / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008327:Mammography; D008875:Middle Aged; D010212:Papilloma / Q000000981:diagnostic imaging / Q000473:pathology; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D013997:Time Factors; D014618:Vacuum